MX2022008392A - Metodo para mejorar la farmacocinetica o aumentar la concentracion de plasma de 3-((metilsulfonil)amino)-2-(((4-fenilci clohexil)oxi)metil)piperidina-1-carboxilato de metilo o una sal del mismo con un inhibidor de citocromo p450. - Google Patents
Metodo para mejorar la farmacocinetica o aumentar la concentracion de plasma de 3-((metilsulfonil)amino)-2-(((4-fenilci clohexil)oxi)metil)piperidina-1-carboxilato de metilo o una sal del mismo con un inhibidor de citocromo p450.Info
- Publication number
- MX2022008392A MX2022008392A MX2022008392A MX2022008392A MX2022008392A MX 2022008392 A MX2022008392 A MX 2022008392A MX 2022008392 A MX2022008392 A MX 2022008392A MX 2022008392 A MX2022008392 A MX 2022008392A MX 2022008392 A MX2022008392 A MX 2022008392A
- Authority
- MX
- Mexico
- Prior art keywords
- methyl
- phenylcyclohexyl
- piperidine
- oxy
- carboxylate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062959514P | 2020-01-10 | 2020-01-10 | |
| PCT/US2021/012447 WO2021142083A1 (en) | 2020-01-10 | 2021-01-07 | A method for enhancing the pharmacokinetics or increasing the plasma concentration of methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate or a salt thereof with an inhibitor of cytochrome p450 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022008392A true MX2022008392A (es) | 2022-08-08 |
Family
ID=74418549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022008392A MX2022008392A (es) | 2020-01-10 | 2021-01-07 | Metodo para mejorar la farmacocinetica o aumentar la concentracion de plasma de 3-((metilsulfonil)amino)-2-(((4-fenilci clohexil)oxi)metil)piperidina-1-carboxilato de metilo o una sal del mismo con un inhibidor de citocromo p450. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12594269B2 (https=) |
| EP (1) | EP4087534A1 (https=) |
| JP (1) | JP7728264B2 (https=) |
| KR (1) | KR20220127245A (https=) |
| CN (1) | CN115226390B (https=) |
| AU (1) | AU2021205892B2 (https=) |
| BR (1) | BR112022013547A2 (https=) |
| CA (1) | CA3167050A1 (https=) |
| MX (1) | MX2022008392A (https=) |
| WO (1) | WO2021142083A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI4065585T3 (fi) | 2019-11-25 | 2025-09-26 | Alkermes Inc | Substituoituja makrosyklisiä yhdisteitä ja niihin liittyviä hoitomenetelmiä |
| US11760747B2 (en) | 2020-12-21 | 2023-09-19 | Alkermes, Inc. | Substituted piperidino compounds and related methods of treatment |
| US12006330B2 (en) | 2020-12-21 | 2024-06-11 | Alkermes, Inc. | Substituted macrocyclic compounds and related methods of treatment |
| AR130709A1 (es) | 2022-10-07 | 2025-01-08 | Kissei Pharmaceutical | Compuesto de ciclopentano |
| KR20250085056A (ko) | 2023-12-05 | 2025-06-12 | 안희태 | 국궁 과녁에서 영역 구분 센서의 구성 방법 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ524104A (en) * | 2000-09-08 | 2004-12-24 | Pharmacia Italia S | Exemestane as chemopreventing agent |
| HK1224173A1 (zh) | 2013-03-14 | 2017-08-18 | Pharmacyclics Llc | 布鲁顿氏酪氨酸激酶抑制剂和cyp3a4抑制剂的组合 |
| PL3411358T3 (pl) | 2016-02-04 | 2022-02-28 | Takeda Pharmaceutical Company Limited | Podstawiony związek piperydynowy i jego zastosowanie |
| CA3032813A1 (en) | 2016-08-04 | 2018-02-08 | Gilead Sciences, Inc. | Cobicistat for use in cancer treatments |
| BR112022004576A2 (pt) | 2019-09-13 | 2022-06-14 | Takeda Pharmaceuticals Co | Métodos para diminuir ou tratar sonolência excessiva, tratar narcolepsia tipo 2 ou hipersonia idiopática, tratar distúrbio de trabalho de turno, aumentar latência de sono em manutenção de teste de insônia, melhorar classificação de escaça de sonolência de karolinska, diminuir ou melhorar sonolência subjetiva, aumentar insônia ou diminuir sonolência excessiva, melhorar classificação de escala de sonolência epworth, tratar narcolepsia tipo 2, diminuir ou tratar sonolência diurna excessiva, e, composição farmacêutica |
| CA3154321A1 (en) | 2019-09-13 | 2021-03-18 | Takeda Pharmaceutical Company Limited | Tak-925 for use in treating narcolepsy |
-
2021
- 2021-01-07 MX MX2022008392A patent/MX2022008392A/es unknown
- 2021-01-07 WO PCT/US2021/012447 patent/WO2021142083A1/en not_active Ceased
- 2021-01-07 CA CA3167050A patent/CA3167050A1/en active Pending
- 2021-01-07 US US17/791,302 patent/US12594269B2/en active Active
- 2021-01-07 EP EP21702564.2A patent/EP4087534A1/en active Pending
- 2021-01-07 AU AU2021205892A patent/AU2021205892B2/en active Active
- 2021-01-07 CN CN202180017795.5A patent/CN115226390B/zh active Active
- 2021-01-07 KR KR1020227023475A patent/KR20220127245A/ko active Pending
- 2021-01-07 JP JP2022542294A patent/JP7728264B2/ja active Active
- 2021-01-07 BR BR112022013547A patent/BR112022013547A2/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021142083A1 (en) | 2021-07-15 |
| BR112022013547A2 (pt) | 2022-09-06 |
| AU2021205892A1 (en) | 2022-08-18 |
| US12594269B2 (en) | 2026-04-07 |
| US20230029486A1 (en) | 2023-02-02 |
| AU2021205892B2 (en) | 2026-04-23 |
| CN115226390B (zh) | 2026-03-20 |
| JP2023510332A (ja) | 2023-03-13 |
| EP4087534A1 (en) | 2022-11-16 |
| JP7728264B2 (ja) | 2025-08-22 |
| KR20220127245A (ko) | 2022-09-19 |
| CA3167050A1 (en) | 2021-07-15 |
| CN115226390A (zh) | 2022-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022008392A (es) | Metodo para mejorar la farmacocinetica o aumentar la concentracion de plasma de 3-((metilsulfonil)amino)-2-(((4-fenilci clohexil)oxi)metil)piperidina-1-carboxilato de metilo o una sal del mismo con un inhibidor de citocromo p450. | |
| CA3174139A1 (en) | Rna-editing compositions and methods of use | |
| EP4628167A3 (en) | Substituted macrocyclic compounds and related methods of treatment | |
| WO2021247543A3 (en) | Nucleic acid library methods | |
| EP4306116A3 (en) | Methods and compositions for editing rnas | |
| EP4015654A4 (en) | COMPOSITION, KIT AND METHOD FOR CORONAVIRUS DETECTION AND TYPING | |
| BR112022003970A2 (pt) | Métodos e composições para integração genômica | |
| BRPI0411378A (pt) | composição polimerizável de duas partes, método de polimerização, método para ligar dois ou mais componentes entre si, método para modificar a superfìcie de um polìmero de energia superficial baixa, método para revestir um substrato, composição de revestimento, laminado e composição polimerizável de uma parte | |
| WO2008027932A3 (en) | Cytochrome p450 oxidase inhibitors and uses thereof | |
| WO2021048821A8 (en) | Use of an orexin 2 receptor agonist for the treatment of excessive sleepiness | |
| DK2111401T3 (da) | 4-{4-[({3-tert-butyl-1-[3-(hydroxymethyl)phenyl]-1H-pyrazol-5-yl}carbamoyl)-amino]-3-fluorphenoxy}-N-methylpyridin-2-carboxamid samt prodrug og salte heraf til behandling af cancer | |
| TN2009000249A1 (en) | Mapk/erk kinase inhibitors | |
| NO20072058L (no) | Inhibitorer av interaksjonen mellom MDM2 og P53 | |
| WO2009145798A3 (en) | Methods for modifying features of a workpiece using a gas cluster ion beam | |
| CR20230100A (es) | Compuestos fosfolípidos y usos de los mismos | |
| ZA202402178B (en) | 3clpro protease inhibitor | |
| MX2022012942A (es) | Metodos que involucran el inhibidor de la elastasa de neutrofilo alvelestat para el tratamiento de enfermedades respiratorias mediadas por deficiencia de alfa-1 antitripsina. | |
| TW200507831A (en) | Combination comprising s-[2-([[1-(2-ethylbutyl)cyclohexyl] carbonyl]amino)phenyl]2-methylpropanethioate and an HMG CoA reductase inhibitor | |
| TWI347627B (en) | Work piece transfer appratus and method for an ion beam implanter | |
| CO2019001046A2 (es) | Mancha blanca | |
| WO2022079128A3 (en) | Compositions and methods for masking off-notes in consumables | |
| MX2026002406A (es) | Degradadores del transductor de señales y activador de la transcripción 6 (stat6) y usos de los mismos | |
| TW200610036A (en) | Improved magnet for scanning ion beams | |
| MX2024014079A (es) | Inhibidores de la proteina cinasa activada por mitogeno (mek) y usos de estos | |
| TW200701429A (en) | Laser beam processing machine |